Pediatric pulmonary vascular disease contributes to morbidities and death in diverse clinical settings, ranging from idiopathic or heritable forms of pediatric arterial hypertension, congenital heart disease, developmental lung disorders, chronic lung disease, left heart disease, sickle cell disease, oncologic disease, and systemic disorders. Despite its impact on the clinical courses in so many diseases, information is limited on how to best approach the diagnosis and evaluation of pediatric pulmonary hypertension.
INTRODUCTION: UNIQUE ASPECTS OF PEDIATRIC PULMONARY VASCULAR DISEASE
Over the past few decades, there has been a growing awareness of the contributions of pulmonary hypertension and related pulmonary vascular diseases (PVDs) to poor outcomes in children with diverse diseases, associated with heart, lung, blood, and systemic conditions [1] [2] [3] . Despite advances in our understanding of its pathobiology and the growing availability of drug therapies, pulmonary hypertension and related PVD continue to cause significant morbidity and mortality. Although pulmonary hypertension is a relatively rare condition, it is surprising how often abnormalities of the pulmonary circulation are found to contribute to the pathophysiology and clinical course in acute and chronic settings. Pulmonary hypertension is present in such settings as the extremely rare form of idiopathic or isolated pulmonary artery hypertension (IPAH) to more common conditions such as acute respiratory failure, chronic lung diseases (such as bronchopulmonary dysplasia; BPD) and hematologic disorders (especially sickle cell disease; SCD), and others. In fact, over the past several years, pulmonary hypertension-related hospitalizations of children have markedly increased, which likely reflects improved recognition of the important role of pulmonary hypertension in these diverse clinical settings [4] .
Despite increased understanding regarding the adverse impact of pulmonary hypertension in many therapeutic strategies for neonates, infants, and children with PAH [1] [2] [3] . Studies are often complicated by the marked heterogeneity of conditions and comorbidities associated with pediatric PVD, the relatively small number of patients at each center, the dependence on anecdotal experience or on studies of adult patients, and other critical factors [3, 5] . Although similarities exist regarding the etiology and disease pathogenesis of some forms of pediatric and adult pulmonary hypertension, many cardiopulmonary and systemic diseases associated with pulmonary hypertension are unique to children [2, 3, 5] . Vascular injury or disruption of lung growth during susceptible periods of lung development can have dramatic and long-standing impacts on the pulmonary circulation throughout childhood, which may impact growth of the distal lung airspace as well. For example, preclinical studies have clearly shown that inhibition of vascular growth during development because of various mechanisms not only increases the subsequent risk for pulmonary hypertension but also impairs alveolarization and can cause sustained abnormalities of distal lung structure [5] [6] [7] . Clinically, the concept KEY POINTS Pediatric pulmonary hypertension, which includes diverse cardiac, pulmonary, systemic, and other disorders, requires rigorous initial diagnostic evaluations; careful and frequent monitoring, including responsiveness to therapies over time; and care at or close collaborations with specialized pulmonary hypertension centers.
Pulmonary hypertension-targeted therapy has improved outcomes in many settings; however, data are limited regarding the unique responses of children to these medications; potential adverse drug effects, especially in newborns and young infants; and optimal markers and endpoints to better assess long-term outcomes.
Interdisciplinary care programs that include teams of subspecialists will likely enhance the care of children with diverse forms of pediatric pulmonary hypertension.
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Size of treatment effect that early echocardiogram evidence of PVD during the first week of life after preterm birth increases respiratory morbidities and the subsequent risk for severe BPD and pulmonary hypertension later during the neonatal intensive care unit course [8] .
Estimate of certinty (precision) of tratment effect
Class IIb
Similarly, PVD and pulmonary hypertension contribute to poor outcomes in many developmental lung diseases, such as alveolar capillary dysplasia, and genetic syndromes, especially in patients with Down syndrome, who are highly susceptible to pulmonary hypertension because of abnormal lung vascular and alveolar development as well as postnatal cardiopulmonary factors [9] . Along with altered lung vascular development, there are striking maturational differences between children and adults regarding responsiveness to PAH-specific drug therapies, pharmacodynamics and pharmacokinetics, and perhaps, the potential for late adverse effects, as reflected by controversies from the sildenafil studies in children [10] [11] [12] [13] . In addition, little is understood regarding critical comorbidities that impact long-term outcomes in specific diseases with pulmonary hypertension; how to best monitor disease progression or response to therapy; and whether early recognition or preventive therapeutic strategies can be applied in children to minimize disease severity during adulthood. There is clearly a need to better define the natural history and course of pediatric PAH; to develop new strategies to identify patients at-risk for development of PAH; and to establish novel approaches to diagnose, monitor disease progression, and treat children with PAH.
To address this gap, a committee of experienced pulmonary hypertension clinicians was established to develop a guidelines document for the care of children with pulmonary hypertension through collaboration of both the American Heart Association (AHA) and American Thoracic Society (ATS) [14 && ]. The purpose of this joint committee was to define a comprehensive set of care recommendations that target high-priority clinical questions, based on a systematic literature review as well as expert opinion. Committee members were selected from medical centers with strong clinical care and research programs in pediatric pulmonary hypertension, and the group was multidisciplinary in nature, including pediatric pulmonologists, cardiologists, intensivists, neonatologists, and translational scientists. All members were thoroughly vetted by the AHA and ATS to avoid actual, potential, or perceived conflicts of interests and relationships with industry. The grading system for scoring the level of evidence and strength of recommendation is provided in Fig. 1 . In addition to general discussion, selected aspects from the published guidelines are presented below.
WHO classification of pulmonary hypertension (Nice) Adapted from [15] .
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DEFINITION AND CLASSIFICATION OF PEDIATRIC PULMONARY HYPERTENSION
The definition of pulmonary hypertension for children is similar to that used for adult pulmonary hypertension, with some important differences, especially during the early transitional period after birth [2, 5] . Pulmonary artery pressure is similar to systemic arterial pressure in utero but rapidly falls after birth, generally achieving typical values observed in normal older children and adults by 2-3 months of age. Pulmonary hypertension is diagnosed when mean pulmonary arterial pressure (PAP) is above 25 mmHg, but the presence of pulmonary hypertensive vascular disease (PHVD) in some types of congenital heart disease (CHD), arteriovenous malformations, or other rare settings can be associated with normal PAP. Pediatric pulmonary hypertension is currently categorized by most through use of a disease classification system from the World Health Organization (WHO) that is also used in adult pulmonary hypertension, which was most recently revised at the 5th World Symposium for Pulmonary Hypertension that was held in Nice, France ( Fig. 2) [15] . At this symposium, the pediatric task force worked to add greater emphasis on such uniquely pediatric disorders as persistent pulmonary hypertension of the newborn (PPHN), developmental lung diseases, and certain forms of CHD and cardiomyopathy [2] . On the basis of concerns regarding the applicability of an adult-focused system for the phenotypic heterogeneity of neonatal and childhood pulmonary hypertension, the Pulmonary Vascular Research Institute, an international collaborative group that was created to promote global research in pulmonary hypertension, proposed a novel system that may prove useful as a pediatric-specific system [16] . The goals of the Panama Classification System are to highlight the phenotypic heterogeneity of PHVD from the fetus to the adolescent and the impact on diagnosis, treatment, and research, but whether this system has clinical utility remains unknown.
Currently, the pulmonary vascular resistance index pediatric diseases classification is bulky, contains overlapping features between categories, and needs further refinement; however, the promise that such a system will better define comorbidities and enable practitioners to better care for children with pulmonary hypertension remains a worthy goal.
Significant delays in making the diagnosis of pulmonary hypertension in children are not uncommon, often occurring years after the onset of disease, which is likely because of nonspecific nature of early symptoms. Children with PAH are often misdiagnosed with more common childhood conditions, such as asthma, prior to making the correct diagnosis of PAH. Because of disease complexity, the relatively limited numbers of cases and the importance of experience with specific diagnostic procedures and therapeutic strategies, the evaluation and care for pediatric pulmonary hypertension patients should be provided or co-managed by specialty pulmonary hypertension centers that include comprehensive, multidisciplinary medical subspecialists, nursing, and social work expertise (Table 1 ) [5] . Routine follow-up visits should be performed, at a minimum, every 3-6 months with more frequent visits for patients with advanced disease or after initiation of/changes to therapy. Those comanaged should be seen, at a minimum biannually by or in consultation with pulmonary hypertension specialty centers. At the time of initial pulmonary hypertension diagnosis, a comprehensive history and physical examination in combination with diagnostic testing for assessment of pulmonary hypertension classification, and formal assessment of cardiac function should be performed. Specifically, a chest X-ray, electrocardiogram, echocardiogram, chest CT with and without contrast, 6-min walk test, laboratory studies including brain natriuretic peptide (BNP) or N-terminal-pro-BNP, and cardiac catheterization should be considered critical components of a thorough evaluation. Other tests such as a sleep study, cardiopulmonary exercise testing, additional laboratory work, magnetic resonance imaging, and lung perfusion scans may have greater value in select populations (as further discussed in reference [14 && ]). Data from several registries have recently added to our knowledge on the incidence and prevalence of several forms of pediatric pulmonary hypertension. Although the true incidence and prevalence of pulmonary hypertension in the pediatric population remain uncertain, recent epidemiologic data from national or international registries estimated an annual incidence of 64 cases per million children [17] [18] [19] [20] 21 && ]. The incidence of [20] . Only 12% of enrolled patients had pulmonary hypertension associated with respiratory diseases, with BPD being the most frequent disorder, yet many single sites have far more patients with BPD with pulmonary hypertension (Group 3 disease) than suggested in the TOPP Registry data. Similarly, the National Pediatric PH Registry of the Netherlands reported that the most common causes of persistent or progressive PAH were PPHN, PAH associated with repair of CHD, and IPAH/HPAH [15] . Yet the incidence or prevalence of pulmonary hypertension associated with neonatal lung diseases, such as PPHN, BPD, (iv) PAH-targeted therapy may be considered in patients with SCD in whom there is confirmation of pulmonary hypertension with marked elevation of PVR without an elevated pulmonary capillary wedge pressure by cardiac catheterization. (Class IIb, Level C) congenital diaphragmatic hernia, and other developmental lung diseases, has been grossly underestimated and little has been written on care guidelines ( ]). These patterns likely reflect practice or referral bias, the use of right heart catheterization as a requirement for enrollment into the registry, or a lack of active engagement of consultant services in more common forms of pediatric pulmonary hypertension. ].
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Survival in pediatric pulmonary hypertension has improved dramatically since the advent of targeted pulmonary hypertension therapies. In contrast with a 3-year survival rate of less than 50% in historic data, the Registry to EValuate Early and Long-Term PAH (REVEAL) reported 1-year, 3-year, and 5-year estimated survival rates in children of 96, 84, and 74%, respectively, with no significant difference between IPAH and CHD-associated PAH [18] . Current recommendations on stepwise approaches to care, including the important role of cardiac catheterization with assessments of acute vasoreactivity and selection of pulmonary hypertension-targeted drug therapy, were also addressed in the recent guidelines document ([14 && ]; Fig. 3 and Table 5 ). Clinical experience and published data related to these recommendations are, however, largely limited to selected forms of pediatric pulmonary hypertension; whether this approach is useful for specific diseases associated with pulmonary hypertension, such as BPD, developmental lung diseases, and others, clearly require further study.
More recently, del Cerro Marin et al. [21 && ] published data from the Spanish PH Registry, which has provided more extensive information on disease incidence, prevalence and the impact of functional class, WHO Group, and other factors on survival. The Spanish Registry included many forms of pulmonary hypertension and thereby provides a more accurate picture of the nature of pulmonary hypertensionrelated disorders in children than past studies. In the Spanish Registry, 61% of the patients had PAH (Group 1), 14% had pulmonary hypertension with left heart disease (Group 2), 18% had pulmonary hypertension associated with respiratory disease (Group 3), 1% had thromboembolic pulmonary hypertension (Group 4), and 4.5% had multifactorial factors (Group 5), including metabolic diseases. Importantly, 31% of the patients had pulmonary hypertension associated with multiple etiologies, suggesting the need for more accurate phenotyping beyond traditional classification schemes alone. This study further showed that independent risk factors for mortality included etiology group, age at diagnosis younger than 2 years, advanced functional class, and high right atrial pressure as assessed by right heart catheterization [16] . Although limited by its retrospective nature, this study provides a more accurate landscape that better reflects diverse causes of pulmonary hypertension commonly seen in pediatric practice. This study further highlights the need to evaluate all causes of pulmonary hypertension and to include collaborations with multidisciplinary teams (e.g., pulmonologists, neonatologists, intensivists, hematologists, and others) to more accurately reflect the full scope of pediatric pulmonary hypertension. The development of high-quality patient registries represents only the beginning of extensive work that must be done in order to more extensively phenotype and characterize the natural history, disease course, response to therapies, and late outcomes of pediatric pulmonary hypertension. Current therapeutic approaches and experience with pulmonary hypertension-targeted drugs remain largely based on small and selected study populations with Group 1 disease ( Fig. 3 and Table 5 ). Although experience is growing in other settings, more clinical data are clearly needed to guide optimal approaches with disease-specific strategies. In addition, more clinical research is needed to better support general supportive outpatient care issues for children with pulmonary hypertension to enhance their quality of life and long-term outcomes ( Table 6) .
As highlighted in a past National Heart Lung and Blood Institute (NHLBI) conference, approaches toward improving outcomes for children with PVD include the need to establish the natural history and longitudinal course of at-risk pediatric patients through more extensive phenotyping in diverse settings; linking clinical data with predictors of disease, such as proteomic, genetic, and epigenetic biomarkers; identifying clinical features to better characterize patients through physiologic assessments with age-appropriate function; to identify clinically-useful endpoints and validated surrogates for performing clinical trials in young children with PAH; and to improve our ability to perform postmarketing surveillance of pulmonary hypertension-specific therapies [22] .
Improving long-term outcomes in pediatric pulmonary hypertension remains limited by the lack of proven clinical or study end-points that can readily be applied to infants and young children. Rigorous registries and perhaps novel informatic strategies may provide deeper explorations of patient phenotypes, better identification of patient populations for clinical trials, lead to the establishment of useful study endpoints and meaningful surrogates to enhance understanding and development of novel therapeutic strategies. Interventional studies and managing children with pulmonary hypertension have been hindered by a lack of adequate end points for rigorous evaluation of outcomes during clinical trials and of treatment goals, and protein biomarkers and events in pediatric pulmonary hypertension.
CONCLUSION
Pediatric pulmonary hypertension remains poorly studied and there is clearly a need to better define the natural history and longitudinal courses of diverse diseases associated with pediatric PAH; to explore unique phenotypes; to develop new strategies to identify at-risk patients early in their course; and to establish novel approaches to diagnose, monitor disease progression, and treat children with pulmonary hypertension. This limitation highlights the critical need for developing high-quality patient registries and related databases of children with diverse forms of PAH for supporting more extensive and high-quality observational and interventional studies. Recently published guidelines provide some recommendations for the care of children with pulmonary hypertension, yet primarily emphasize ongoing gaps in knowledge and the need for more extensive clinical investigations to better improve long-term outcomes.
